Bill · 119th Congress
H.R. 10857
To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
- 01 Introduced
- 02 Committee
- 03 Passed House
- 04 Passed Senate
- 05 To President
- 06 Law
Latest action · Oct 22, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What this bill does
No summary yet
How Congress voted
No recorded votes yet. Many bills pass by voice vote or unanimous consent, where no one's individual vote is written down.
Timeline
- Oct 22, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Oct 22, 2026Introduced in House
Cosponsors
1 member
- H. Morgan GriffithR-VA-9
Details
Related bills
None listed
Cost estimates · Congressional Budget Office
None published